The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle

Brian A. Clarke, Doreen Drujan, Monte Willis, Leon O. Murphy, Richard A. Corpina, Elena Burova, Sergey V. Rakhilin, Trevor N. Stitt, Cam Patterson, Esther Latres, David J. Glass

Research output: Contribution to journalArticle

363 Citations (Scopus)

Abstract

Skeletal muscle atrophy occurs as a side effect of treatment with synthetic glucocorticoids such as dexamethasone (DEX) and is a hallmark of cachectic syndromes associated with increased cortisol levels. The E3 ubiquitin ligase MuRF1 (muscle RING finger protein 1) is transcriptionally upregulated by DEX treatment. Differentiated myotubes treated with DEX undergo depletion of myosin heavy chain protein (MYH), which physically associates with MuRF1. This loss of MYH can be blocked by inhibition of MuRF1 expression. When wild-type and MuRF1-/- mice are treated with DEX, the MuRF1-/- animals exhibit a relative sparing of MYH. In vitro, MuRF1 is shown to function as an E3 ubiquitin ligase for MYH. These data identify the mechanism by which MYH is depleted under atrophy conditions and demonstrate that inhibition of a single E3 ligase, MuRF1, is sufficient to maintain this important sarcomeric protein.

Original languageEnglish (US)
Pages (from-to)376-385
Number of pages10
JournalCell Metabolism
Volume6
Issue number5
DOIs
StatePublished - Nov 7 2007
Externally publishedYes

Fingerprint

Ubiquitin-Protein Ligases
Myosin Heavy Chains
Dexamethasone
Skeletal Muscle
Muscles
Proteins
Muscular Atrophy
Skeletal Muscle Fibers
Glucocorticoids
Atrophy
Hydrocortisone
Therapeutics

Keywords

  • HUMDISEASE

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology

Cite this

Clarke, B. A., Drujan, D., Willis, M., Murphy, L. O., Corpina, R. A., Burova, E., ... Glass, D. J. (2007). The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle. Cell Metabolism, 6(5), 376-385. https://doi.org/10.1016/j.cmet.2007.09.009

The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle. / Clarke, Brian A.; Drujan, Doreen; Willis, Monte; Murphy, Leon O.; Corpina, Richard A.; Burova, Elena; Rakhilin, Sergey V.; Stitt, Trevor N.; Patterson, Cam; Latres, Esther; Glass, David J.

In: Cell Metabolism, Vol. 6, No. 5, 07.11.2007, p. 376-385.

Research output: Contribution to journalArticle

Clarke, BA, Drujan, D, Willis, M, Murphy, LO, Corpina, RA, Burova, E, Rakhilin, SV, Stitt, TN, Patterson, C, Latres, E & Glass, DJ 2007, 'The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle', Cell Metabolism, vol. 6, no. 5, pp. 376-385. https://doi.org/10.1016/j.cmet.2007.09.009
Clarke, Brian A. ; Drujan, Doreen ; Willis, Monte ; Murphy, Leon O. ; Corpina, Richard A. ; Burova, Elena ; Rakhilin, Sergey V. ; Stitt, Trevor N. ; Patterson, Cam ; Latres, Esther ; Glass, David J. / The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle. In: Cell Metabolism. 2007 ; Vol. 6, No. 5. pp. 376-385.
@article{6f3dd9db7c1c4f1e92d8d174a0db0657,
title = "The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle",
abstract = "Skeletal muscle atrophy occurs as a side effect of treatment with synthetic glucocorticoids such as dexamethasone (DEX) and is a hallmark of cachectic syndromes associated with increased cortisol levels. The E3 ubiquitin ligase MuRF1 (muscle RING finger protein 1) is transcriptionally upregulated by DEX treatment. Differentiated myotubes treated with DEX undergo depletion of myosin heavy chain protein (MYH), which physically associates with MuRF1. This loss of MYH can be blocked by inhibition of MuRF1 expression. When wild-type and MuRF1-/- mice are treated with DEX, the MuRF1-/- animals exhibit a relative sparing of MYH. In vitro, MuRF1 is shown to function as an E3 ubiquitin ligase for MYH. These data identify the mechanism by which MYH is depleted under atrophy conditions and demonstrate that inhibition of a single E3 ligase, MuRF1, is sufficient to maintain this important sarcomeric protein.",
keywords = "HUMDISEASE",
author = "Clarke, {Brian A.} and Doreen Drujan and Monte Willis and Murphy, {Leon O.} and Corpina, {Richard A.} and Elena Burova and Rakhilin, {Sergey V.} and Stitt, {Trevor N.} and Cam Patterson and Esther Latres and Glass, {David J.}",
year = "2007",
month = "11",
day = "7",
doi = "10.1016/j.cmet.2007.09.009",
language = "English (US)",
volume = "6",
pages = "376--385",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle

AU - Clarke, Brian A.

AU - Drujan, Doreen

AU - Willis, Monte

AU - Murphy, Leon O.

AU - Corpina, Richard A.

AU - Burova, Elena

AU - Rakhilin, Sergey V.

AU - Stitt, Trevor N.

AU - Patterson, Cam

AU - Latres, Esther

AU - Glass, David J.

PY - 2007/11/7

Y1 - 2007/11/7

N2 - Skeletal muscle atrophy occurs as a side effect of treatment with synthetic glucocorticoids such as dexamethasone (DEX) and is a hallmark of cachectic syndromes associated with increased cortisol levels. The E3 ubiquitin ligase MuRF1 (muscle RING finger protein 1) is transcriptionally upregulated by DEX treatment. Differentiated myotubes treated with DEX undergo depletion of myosin heavy chain protein (MYH), which physically associates with MuRF1. This loss of MYH can be blocked by inhibition of MuRF1 expression. When wild-type and MuRF1-/- mice are treated with DEX, the MuRF1-/- animals exhibit a relative sparing of MYH. In vitro, MuRF1 is shown to function as an E3 ubiquitin ligase for MYH. These data identify the mechanism by which MYH is depleted under atrophy conditions and demonstrate that inhibition of a single E3 ligase, MuRF1, is sufficient to maintain this important sarcomeric protein.

AB - Skeletal muscle atrophy occurs as a side effect of treatment with synthetic glucocorticoids such as dexamethasone (DEX) and is a hallmark of cachectic syndromes associated with increased cortisol levels. The E3 ubiquitin ligase MuRF1 (muscle RING finger protein 1) is transcriptionally upregulated by DEX treatment. Differentiated myotubes treated with DEX undergo depletion of myosin heavy chain protein (MYH), which physically associates with MuRF1. This loss of MYH can be blocked by inhibition of MuRF1 expression. When wild-type and MuRF1-/- mice are treated with DEX, the MuRF1-/- animals exhibit a relative sparing of MYH. In vitro, MuRF1 is shown to function as an E3 ubiquitin ligase for MYH. These data identify the mechanism by which MYH is depleted under atrophy conditions and demonstrate that inhibition of a single E3 ligase, MuRF1, is sufficient to maintain this important sarcomeric protein.

KW - HUMDISEASE

UR - http://www.scopus.com/inward/record.url?scp=35548973391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548973391&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2007.09.009

DO - 10.1016/j.cmet.2007.09.009

M3 - Article

VL - 6

SP - 376

EP - 385

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 5

ER -